AL

Rapidio Introduces Data Platform, Transforming Mortgage Lending with Superior Data Accuracy and Security

Retrieved on: 
Thursday, November 9, 2023
Software, Finance, Banking, Data Management, Professional Services, Technology, Fintech, Security, Privacy, Tuch, Microsoft, Anomaly, AI, Fraud, AL, Risk, Machine learning, Action Replay, Cryptocurrency, RapidIO

Rapidio , a pioneer of mortgage underwriting technology, announced availability of its data platform to safely transform mortgage lending with speed, accuracy and security.

Key Points: 
  • Rapidio , a pioneer of mortgage underwriting technology, announced availability of its data platform to safely transform mortgage lending with speed, accuracy and security.
  • Powered by its proprietary Al technology, Rapidio’s data platform provides lenders with accurate, reliable data extraction to improve data accuracy, reduce risk, streamline processes and help meet regulatory compliance requirements.
  • With regulatory bodies tightening their grip on data privacy laws, ensuring data security is also not just about protecting your clients but about staying compliant and avoiding hefty penalties.”
    Rapidio’s data platform is designed with robust security measures that protect user data at every step of the mortgage lending process.
  • By embracing a solution that scales with a lender’s business and prioritizes data security, Rapidio is redefining the future of mortgage lending and making it safer, smarter and better.

U.S. Army awards Textron Aviation contract for three Beechcraft King Air turboprops

Retrieved on: 
Tuesday, November 7, 2023
Government Technology, Aerospace, Manufacturing, Defense, Air, Transport, White House, Federal Government, Insurance, Other Defense, Contracts, Finance, Homeland Security, Professional Services, Other Energy, Public Policy, Government, Energy, Other Manufacturing, Military, Chemicals, Plastics, Textron Aviation, Cessna, NYSE, Redstone Arsenal, Foreign, COTS, AL, Foreign Military Sales, Cessna 408 SkyCourier, Acquisition, Beechcraft King Air, Multimedia, Aviation, United States Department of the Army, ISR, Fuerza, Textron, IDIQ, Army, FMS, Acceleration, Jet fuel

Textron Aviation today announced it has been awarded a contract by the U.S. Army Contracting Command, Redstone Arsenal, AL, for Cessna SkyCourier , Cessna Grand Caravan EX , Beechcraft King Air 360 and Beechcraft King Air 260 turboprop aircraft in support of Foreign Military Sales (FMS).

Key Points: 
  • Textron Aviation today announced it has been awarded a contract by the U.S. Army Contracting Command, Redstone Arsenal, AL, for Cessna SkyCourier , Cessna Grand Caravan EX , Beechcraft King Air 360 and Beechcraft King Air 260 turboprop aircraft in support of Foreign Military Sales (FMS).
  • The indefinite delivery, indefinite quantity (IDIQ) contract allows up to $100 million U.S. dollars for the acquisition of Textron Aviation aircraft over a five-year period.
  • View the full release here: https://www.businesswire.com/news/home/20231107736088/en/
    Beechcraft King Air 360 (Photo: Business Wire)
    The Cessna SkyCourier, Cessna Grand Caravan EX and Beechcraft King Air are designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company.
  • “We are honored the U.S. Army created this multiyear IDIQ contract with Textron Aviation, which provides the ability to rapidly procure COTS aircraft and modification for FMS allies and partner nations.”
    When government, military and commercial customers want airborne solutions for critical missions, they turn to Textron Aviation.

VMware and Google Cloud announce planned PostgreSQL-compatible Database Solution for traditional and generative AI applications on VMware Cloud Foundation

Retrieved on: 
Tuesday, November 7, 2023
Networks, Internet, Data Management, Technology, Software, Cloud, Omni, Cloud database, VMware, VMW, NYSE, PostgreSQL, Organization, Google Cloud, Access, Database, AL, Partnership, Web data services, Running, AI, GOOG, Network equipment provider, Video game, Online shopping, VSAN

VMware Explore 2023 – Today, VMware, Inc. (NYSE: VMW) and Google Cloud (NASDAQ: GOOG) announced an expanded partnership to deliver Google Cloud’s AlloyDB Omni database on VMware Cloud Foundation, starting with on-premises private clouds.

Key Points: 
  • VMware Explore 2023 – Today, VMware, Inc. (NYSE: VMW) and Google Cloud (NASDAQ: GOOG) announced an expanded partnership to deliver Google Cloud’s AlloyDB Omni database on VMware Cloud Foundation, starting with on-premises private clouds.
  • AlloyDB Omni will be the first third-party PostgreSQL-compatible database natively integrated with VMware Cloud Foundation through VMware Data Services Manager and VMware vSAN.
  • The upcoming delivery of AlloyDB Omni on VMware Cloud Foundation will give customers access to an enterprise-grade version of PostgreSQL with full enterprise support from Google Cloud.
  • Google-powered AI capabilities: VMware Cloud customers can smoothly build enterprise-grade applications with AlloyDB AI, an integral part of AlloyDB Omni.

AltaPointe Health plans hiring events to fill open positions across its continuum

Retrieved on: 
Monday, November 6, 2023
Federally Qualified Health Center, Learning, Health, Patient, Calendar, Career Opportunities, Human, Career Opportunities (film), AL, Nursing, Management

MOBILE, Ala., Nov. 6, 2023 /PRNewswire-PRWeb/ -- As the year draws to a close, AltaPointe Health has two opportunities for job seekers to cap off 2023 by landing their potential dream job. These end-of-year events bring together job seekers and employers in a dynamic and interactive setting. With the job market constantly evolving, these hiring events offer unique chances for candidates to stand out, make meaningful connections, and secure employment before the year ends.

Key Points: 
  • AltaPointe Health is holding year-end hiring events to help you cap off 2023 by landing a job in healthcare.
  • AltaPointe recruiters are equally enthusiastic about the hiring events, as it allows them to access a pool of motivated candidates.
  • Now focusing on the patient's whole health, its Federally Qualified Health Center is open with five clinic sites.
  • Rounding out the continuum, AltaPointe has two psychiatric hospitals serving children and adults, a 24-hour behavioral health crisis center, and 23 outpatient behavioral healthcare clinics.

Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Retrieved on: 
Monday, November 6, 2023
AL, Treatment, MD, AL amyloidosis, Society, ASH, LOS, MGUS, Exposition, Patient, Pharmaceutical industry, Amyloidosis

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq:IMMX) (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “NXC-201 is the only CAR-T being studied as a treatment for AL amyloidosis patients who relapsed, or are refractory to, 4-drug combination daratumumab-CyBorD,” said Ilya Rachman, MD PhD, Executive Chairman of Nexcella.
  • “NXC-201 attacks the root cause of AL Amyloidosis: disease-causing plasma cells, representing a potential one-time treatment option.”
    “30,000 – 45,000 patients in the United States and Europe are living with AL Amyloidosis, for many of whom there are no additional approved treatment options beyond Dara-CyBorD,” said Gabriel Morris, President of Nexcella.
  • “We are pleased to present our progress on advancing NXC-201 at the upcoming 65th annual ASH meeting in San Diego.”
    65th ASH Annual Meeting and Exposition, San Diego, CA
    Session Name: 654.
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Retrieved on: 
Monday, November 6, 2023
AL, Treatment, MD, AL amyloidosis, Society, ASH, LOS, MGUS, Exposition, Patient, Pharmaceutical industry, Amyloidosis

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “NXC-201 is the only CAR-T being studied as a treatment for AL amyloidosis patients who relapsed, or are refractory to, 4-drug combination daratumumab-CyBorD,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma.
  • “NXC-201 attacks the root cause of AL Amyloidosis: disease-causing plasma cells, representing a potential one-time treatment option.”
    “30,000 – 45,000 patients in the United States and Europe are living with AL Amyloidosis, for many of whom there are no additional approved treatment options beyond Dara-CyBorD,” said Gabriel Morris, Chief Financial Officer of Immix Biopharma.
  • “We are pleased to present our progress on advancing NXC-201 at the upcoming 65th annual ASH meeting in San Diego.”
    65th ASH Annual Meeting and Exposition, San Diego, CA
    Session Name: 654.
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis

Individual with Down Syndrome Runs First World Major at the TCS New York City Marathon

Retrieved on: 
Thursday, November 2, 2023
National Down Syndrome Society, Social media, AL, Parade, DE, Daniel, World Marathon Majors, NDSS, Down syndrome, Dream, TCS, New York City Marathon, Nightclub, Nation

New York, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daniel Chaplin, 33, of Homewood, AL will be running in the TCS New York City Marathon for the National Down Syndrome Society (NDSS) on November 5th.

Key Points: 
  • New York, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daniel Chaplin, 33, of Homewood, AL will be running in the TCS New York City Marathon for the National Down Syndrome Society (NDSS) on November 5th.
  • This will be Daniel’s second marathon and his first World Marathon Major.
  • “It really means a lot to me to run and march in the New York City Marathon and the Parade of Nations,” said Daniel.
  • “We are thrilled to have Daniel represent NDSS in a World Marathon Major,” said NDSS President & CEO Kandi Pickard.

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Amyloid, Survival, FDA, Bristol Myers Squibb, Research, Organ dysfunction, AD, IND, PD, Food, VITAL, ATTR, Therapy, Fast track (FDA), AL, Mortality, G&A, Novo Nordisk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acquisition, European Medicines Agency, American Society of Hematology, MAD, SAD, Orphan, R, TTR, ASH, Clinical trial, Biology, Risk, Alpha-synuclein, Epitope, Amyloidosis, Society, SPA, Patient, Failure, Pharmaceutical industry, Vaccine, Fine chemical, Security (finance), Blood

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.
  • Robust reduction of brain amyloid plaque has been demonstrated to likely predict clinical benefit for people with early AD.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PRX012 for the treatment of AD.
  • As of September 30, 2023, Prothena had $673.1 million in cash, cash equivalents and restricted cash, and no debt.

Legendary Northern California Music Venue Sweetwater Music Hall Celebrates 51st Anniversary With The Tubes & DJ Logic

Retrieved on: 
Monday, November 6, 2023
Steely Dan, Wood, The Completion Backward Principle, Beauty, Capitol Records, A&M, A&M Records, Blues Traveler, Sushi Girl, The Tubes, DJ, Billboard, White Punks on Dope, DJ Logic, Red, Young and Rich, Drum, Mötley Crüe, AL, MTV, Tube, Music, Mos Def, O.A.R, Remote control, General ticket, Map, Root, Fifty Foot Hose, Life insurance, Nightclub, Life

MILL VALLEY, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Legendary non-profit music venue Sweetwater Music Hall celebrates its 51st Anniversary on Friday, November 17, 2023 with a benefit gala featuring a special performance by iconic San Francisco band The Tubes (featuring Prairie Prince and Fee Waybill) with DJ Logic and a live auction with one-of-a-kind items and experiences. The event is a fundraiser for Sweetwater Music Hall, a non-profit arts organization that is fully committed to advancing education, understanding and appreciation of music, Bay Area music history, culture, and arts, through the presentation of a vibrant and diverse range of performances, exhibits, and arts programming to the general public, with particular focus on youth arts education.

Key Points: 
  • As a General Ticket Holder you will receive the following:
    *$100 of your ticket purchase is tax deductible.
  • The Tubes formed in 1972 in San Francisco from two bands that moved there from Phoenix, The Beans along with the Red, White and Blues Band.
  • All these years later, The Tubes still consists of, original members, the irrepressible front man Fee Waybill, world-class drummer Prairie Prince, and virtuoso guitarist Roger Steen.
  • Led by singer Fee Waybill – known for his classic characters, including the glam-rocking, stackheeled Quay Lewd, the dangerous Mr.